EQS-News: Apogenix AG: Apogenix' Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme

EQS-News: Apogenix AG / Key word(s): Study/Study results Apogenix' Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept

Related Keywords

Hong Kong ,Wei Kuo Chen ,Shanxi ,China ,Macao ,Macau General ,Macau ,Taiwan ,Switzerland ,Germany ,United States ,Chang Gung Memorial Hospital ,Taoyuan Xian ,Beijing ,Lugano ,Ticino ,Heidelberg ,Baden Wüberg ,American ,Katja Arnold ,Hsiu Chi Chen ,Chia Hua Chen ,Chia Wen Huang ,Hong Chieh Tsai ,Linkou Chang Gung ,James Xue ,Brigitte Keller ,Kuo Chen Wei ,Iyu Lin ,Judith Teumer ,Ian Yi Feng Chang ,Ya Jui Lin ,Gerry Cox ,Ting Chen ,Thomas Hoeger ,Canbridge Pharmaceuticals ,Canbridge Life Sciences ,Canbridge Pharmaceuticals Inc ,Mc Services ,Rare Cancers Annual Congress ,Distribution Services ,American Association Of Neurological Surgeons ,European Medicines Agency ,European Society Of Medical Oncologists ,Five Year Overall Survival Rate Compared ,Newly Diagnosed Glioblastoma Multiforme ,Rare Cancers Annual ,American Association ,Neurological Surgeons ,Term Data ,Glioblastoma Multiforme Shows ,Five Year Overall Survival Rate ,European Society ,Medical Oncologists ,New Taipei City Tucheng ,Fang Min Huang ,You Yu Lin ,Ko Ting Chen ,Linkou Chang Gung Memorial Hospital ,Life Sciences ,Corporate News ,Regulatory Announcements ,News ,Apogenix ,Partner ,Banbridge ,Nnounces ,Five ,Ear ,Verall ,Survival ,Gate ,Ompared ,Nstitutional ,Database ,Ith ,Sunercept ,Plus ,Standard ,Mare ,Ewly ,Diagnosed ,Glioblastoma ,Ultiform ,